Summit Securities Group LLC Sells 17,877 Shares of CVS Health Corporation $CVS

Summit Securities Group LLC decreased its position in CVS Health Corporation (NYSE:CVS) by 94.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,009 shares of the pharmacy operator’s stock after selling 17,877 shares during the quarter. Summit Securities Group LLC’s holdings in CVS Health were worth $72,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Hamlin Capital Management LLC acquired a new stake in CVS Health in the fourth quarter valued at about $160,844,000. Capitolis Liquid Global Markets LLC acquired a new stake in shares of CVS Health in the 3rd quarter valued at approximately $11,308,000. National Bank of Canada FI grew its holdings in shares of CVS Health by 50.3% during the 3rd quarter. National Bank of Canada FI now owns 1,770,840 shares of the pharmacy operator’s stock valued at $133,495,000 after purchasing an additional 593,015 shares during the last quarter. State Street Corp increased its position in CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH increased its position in CVS Health by 2.9% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 725,189 shares of the pharmacy operator’s stock worth $57,551,000 after purchasing an additional 20,217 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health declared a quarterly dividend of $0.665 per share, reinforcing its shareholder-return policy and signaling management confidence in cash generation. CVS Health declares quarterly dividend
• Positive Sentiment: Coverage around CVS highlighted the company as a likely beneficiary of managed-care consolidation, with commentary that Aetna is handling medical costs and that CVS is well positioned as Walgreens weakens. Cramer’s Stop Trading: CVS Health
• Neutral Sentiment: A CVS executive, Ali Keshavarz, was appointed to the board of Choice Hotels; this is notable for the executive’s profile but does not appear to have a direct operational impact on CVS. Choice Hotels (CHH) Appoints CVS Data Chief To Board As Index Changes Hit
• Negative Sentiment: CVS and Omnicare agreed to a $440 million settlement with the U.S. Department of Justice to resolve improper billing allegations, which creates a large one-time legal cost and keeps regulatory pressure on the company. CVS, Omnicare ink $440M deal with DoJ to resolve improper billing case
• Negative Sentiment: CVS also settled a separate $36.5 million case tied to false Medicaid insulin claims, adding to the legal overhang and reinforcing concerns about compliance risks. CVS settles for $36.5M over false Medicaid insulin claims, Minnesota recovers $400K

Insider Activity at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

CVS Health Trading Up 1.3%

NYSE CVS traded up $1.34 on Friday, reaching $104.15. The company had a trading volume of 9,355,762 shares, compared to its average volume of 7,101,005. The firm has a market cap of $132.88 billion, a price-to-earnings ratio of 45.88, a P/E/G ratio of 1.01 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $106.15. The business has a 50 day moving average of $96.91 and a two-hundred day moving average of $84.17.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the previous year, the company posted $2.25 EPS. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.6%. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CVS shares. Piper Sandler restated an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Mizuho increased their price target on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. JPMorgan Chase & Co. raised their price objective on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. UBS Group increased their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Finally, Wells Fargo & Company lifted their price target on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Twenty-one analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $102.84.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.